Gilead Sciences, Inc (NASDAQ:GILD) shares traded 1.18% higher at $117.41 on Wall Street last session.
GILD stock price is now 17.90% away from the 50-day moving average and 38.85% away from the 200-day moving average. The market capitalization of the company currently stands at $146.22B.
With the price target enhanced from $115 to $132, Oppenheimer maintained Outperform rating for Gilead Sciences, Inc (NASDAQ: GILD). On February 18, 2025, Deutsche Bank Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock keeping its target price maintained at $120, while ‘DZ Bank’ rates the stock as ‘Buy’
In other news, MERDAD V PARSEY, Officer bought 21,910 shares of the company’s stock on Mar 03 ’25. The stock was bought for $2,534,913 at an average price of $115.70. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 18 ’25, 10% Owner GILEAD SCIENCES, INC. bought 1,363,636 shares of the business’s stock. A total of $14,999,996 was incurred on buying the stock at an average price of $11.00. This leaves the insider owning 31,424,760 shares of the company worth $3.69 billion. A total of 0.19% of the company’s stock is owned by insiders.
During the past 12 months, Gilead Sciences, Inc has had a low of $62.07 and a high of $117.39. As of last week, the company has a debt-to-equity ratio of 1.41, a current ratio of 1.60, and a quick ratio of 1.45.
The net profit margin was 1.67% and return on equity was 2.28% for GILD. The company reported revenue of $7.57 billion for the quarter, compared to $7.11 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 6.4 percent.
